Compare Ascendis Pharma A/S (ASND) vs Nutrien Ltd (NTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Nutrien Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Nutrien Ltd trades at $65.84 (market cap $31.29B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays a 3.36% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NTR | |
|---|---|---|
Market Cap | $17.74B | $31.29B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $83.94 |
52-Week Low | $163.32 | $53.64 |
Enterprise Value | $18.11B | $44.46B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Nutrien (NTR) trades at $65.43, up 1.33% today, with a neutral technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by record potash volumes. The stock shows solid fundamentals with a P/E of 13.33 and ROE of 9.7%, though revenue has declined from 2022 peaks. A dividend of $0.55 per share is scheduled for July 2026, supporting income appeal.
Outlook remains positive with a consensus price target of $80.14, reflecting 22% upside potential. Risks include volatile fertilizer prices and geopolitical impacts on agriculture markets. Institutional sentiment is bullish, with 64% of analysts rating it Buy, but investors should monitor debt levels and global demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
